0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Rofecoxib and the Risk of Adverse Upper Gastrointestinal Effects—Reply

Michael J. Langman, MD
JAMA. 2000;283(15):1960-1961. doi:10.1001/jama.283.15.1957.
Text Size: A A A
Published online

Extract

In Reply: Although rofecoxib is designated an NSAID, it differs biochemically from the comparator NSAIDs used in our analysis in that it specifically inhibits cyclooxygenase 2 (COX-2) and does not inhibit cyclooxygenase 1 (COX-1) at the doses tested.13 Thus, as stated in our article, "The primary hypothesis involved a biologically meaningful comparison of GI [gastrointestinal] safety with COX-2 specific inhibition versus nonspecific COX-1/COX-2 inhibition." Dr Freston is correct that the test for treatment by protocol interaction suffers from low power. We noted that there were generally too few events within any single protocol to provide precise study-specific results, and we outlined the analyses conducted to evaluate the appropriateness of assuming a common RR. We acknowledged that no PUBs occurred with nabumetone in the 1 small study that included it. It is worth noting that no PUBs occurred with rofecoxib in that study either, making that study uninformative in the combined analysis.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();